Media kit: Dr. Damon Tojjar

Short bio

Dr. Damon Tojjar is a physician-scientist and digital health entrepreneur whose work spans global drug development, clinical AI, and medical-device regulation, with research roots in diabetes genetics and metabolic disease. Trained in medicine at Lund University and in systems medicine at Stanford, his diabetes-genetics research includes a shared (co-second) author contribution to a paper in Science, recognized with the Magnus Blix Award, and a Diabetes Care meta-analysis cited more than 800 times. He co-developed EASY Diabetes, an AI decision-support system that won Sweden's Medtech4Health Innovation Award, and co-founded Vi-Health, which was selected as one of 20 finalists (Top 20 Deep Tech) in the EIT Digital Challenge and later acquired by Numan.

Long bio

Dr. Damon Tojjar is a physician-scientist (M.D., Ph.D. candidate) and digital health entrepreneur whose work spans leading institutions in Europe and the United States. He earned his M.D. at Lund University, whose medical school had the lowest acceptance rate in Sweden at the time of his admission, and achieved top-percentile results on the national medical board examinations. He trained as a Research Fellow in Systems Medicine at Stanford University School of Medicine under Professor Atul Butte, where he was an Anna Lindh Fellow. His doctoral research, based at the Lund University Diabetes Centre, focuses on the genetics of type 2 diabetes.

He was a shared (co-second) author, with equal contribution, on "Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes" (Science), work honored with the Magnus Blix Award. He co-authored a systematic review and meta-analysis in Diabetes Care cited more than 800 times (paper-level), and contributed to CD44 and adipose-inflammation research acknowledged in Kodama et al., Diabetes (2015).

Bridging research and industry, he served as International Medical Manager and Principal Medical Specialist in global development at Novo Nordisk, helping lead global clinical programs for GLP-1 and insulin therapies, including Tresiba, Ryzodeg, and Xultophy. He co-developed EASY Diabetes, an AI decision-support system that earned Sweden's Medtech4Health Innovation Award, and co-founded Vi-Health, which was selected as one of 20 finalists (Top 20 Deep Tech) in the European Institute of Innovation and Technology's EIT Digital Challenge and was later acquired by Numan. He mentors early-career scientists and founders, including through the Nucleate biotech program and as a mentor with UCLA Ventures, and has served as a board member of Lund University's innovation and holding companies, LU Innovation (now LU Ventures) and LU Holding.